China's hepatitis scourge tackled in joint venture:
This article was originally published in Clinica
The diagnosis of viral hepatitis, one of China's major public health problems, is to be tackled by a joint venture between the Chinese and Australian governments. More than US$1.1 million will be invested in upgrading the equipment at Beijing Biochemical and Immune Reagents Centre. The aim is to make it a reference centre for hepatitis diagnosis within two and a half years. China has at least 160 million hepatitis virus carriers and the disease has the highest mortality and incidence rates of all infectious diseases in the country.